Matthew Stork, CEO of Cambridge Cognition said:
“We are delighted that Debra has joined the Board. Debra brings with her an immense amount of knowledge and expertise in successful global medical technology businesses and clinical trial management within major pharmaceutical companies. Her experience will be invaluable as we continue the growth of Cambridge Cognition.”
Cambridge Cognition Holdings plc (LON:COG), the neuroscience technology company, which develops and markets neuroscience technologies to assess brain health, today announced the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
Debra is currently CEO of Vertual, the leading provider of virtual and augmented reality training simulation systems in radiotherapy. She has over 25 years of experience in the medical technology and biotechnology industries, and has previously been COO of Beckley Canopy Therapeutics, CEO of Physeon and also held senior roles with companies such as Rex Bionics, Avita Medical, Merck, GlaxoSmithKline, GE Healthcare and Pfizer.
The following information regarding Debra Marie Leeves (aged 57) is disclosed under Schedule 2(g) of the AIM Rules for Companies:
|Current Directorships||Directorships held in past 5 years|
|Vertual LimitedOxford Box LtdDML Solutions Limited||Physeon GmbH|
As at the date of this announcement, Mrs Leeves is not beneficially interested in any Ordinary Shares in the Company.